Large Funding Round for Massachusetts Biotech Syros

October 27, 2014 | Syros Pharmaceuticals, a biotech focused on creating drugs that target gene expression regulatory pathways, has announced a $53 million Series B financing round. Coming on top of a $30 million Series A round, this latest investment gives the Watertown, MA, company an exceptionally large funding pool to pursue clinical trials. Syros plans to expand beyond its current lead therapeutic areas in cancer and explore more early leads in diseases that could be treated by targeting molecules upstream of key disregulated genes. Xconomy